To investigate whether miR‐19 is a bona fide target regulated by IDH mutation, we treated the three IDHwt glioma cell lines (SF295, A172, and U87) with 5 μm D2HG (a key metabolic product resulting from an IDH mutation) and found a significant induction of miR‐19a. This evidence concerns the gene IDH1 and central nervous system cancer.